V. Kovess, S. Choppin, F. Gao, M. Pivette, M. Husky et al., Psychotropic medication use in French children and adolescents, J Child Adolesc Psychopharmacol, vol.25, pp.168-75, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01147097

H. Verdoux, M. Tournier, and B. Bégaud, Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies, Acta Psychiatr Scand, vol.121, pp.4-10, 2010.

D. Vidal, , 2018.

D. Cohen, Les antipsychotiques atypiques chez l'adolescent : quels enjeux pour l'avenir ?, Encephale, vol.37, pp.15-22, 2011.

M. L. Menard, S. Thümmler, M. Giannitelli, B. Olliac, O. Bonnot et al., Incidence of adverse events in antipsychotic-naïve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE), BMJ Open, vol.6, p.11020, 2016.

, Le bon usage des antidépresseurs chez l'enfant et l'adolescent. Mise au point, AFSSAPS

E. Vieta and F. Colom, Therapeutic options in treatment-resistant depression, Ann Med, vol.43, pp.512-542, 2011.

L. Samalin, S. Guillaume, P. Courtet, M. Abbar, S. Lancrenon et al., Society for Biological Psychiatry and Neuropsychopharmacology task force. Formal consensus for the treatment of bipolar disorder: an update, Encephale, vol.41, pp.93-102, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02142109

T. Suzuki, R. G. Mulsant, B. H. Uchida, H. Rajji, T. K. Graff-guerrero et al., Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation, Psychiatry Res, vol.197, pp.1-6, 2012.

, Guideline on clinical investigation of medicinal products in the treatment of depression

, Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia

, Disponible sur

K. Trevino, S. M. Mcclintock, M. Fischer, N. Vora, A. Husain et al., Defining treatment-resistant depression: a comprehensive review of the literature, Ann Clin Psychiatry, vol.26, pp.222-254, 2014.

Y. Guéguen, K. Mouzat, L. Ferrari, E. Tissandie, J. Lobaccaro et al., Les cytochromes P450 : métabolisme des xénobiotiques, régulation et rôle en clinique, Ann Biol Clin, vol.64, pp.535-583, 2006.

J. H. Lin and A. Y. Lu, Inhibition and induction of cytochrome P450 and the clinical implications, Clin Pharmacokinet, vol.35, pp.361-90, 1998.

C. C. Ogu and J. L. Maxa, Drug interactions due to cytochrome P450, Proc Bayl Univ Med Cent, vol.13, pp.421-424, 2000.

J. Van-der-weide and J. W. Hinrichs, The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications, Clin Biochem Rev, vol.27, pp.17-25, 2006.

S. Quaranta, J. Dupouey, R. Colle, and C. Verstuyft, Pharmacogénétique des médicaments antidépresseurs: état des connaissances et des pratiques-recommandations du Réseau national de pharmacogénétique (RNPGx), Therapie, vol.72, pp.301-310, 2017.

S. Thümmler, E. Dor, R. David, G. Leali, M. Battista et al., Pharmacoresistant severe mental health disorders in children and adolescents: functional abnormalities of cytochrome P450 2D6, Front Psychiatry, vol.9, issue.2, 2018.

, Table des interactions, p.2017

D. Sur,

A. Fernandez, E. Dor, M. L. Menard, F. Askenazy, and S. Thümmler, Surdosage en carbamazépine par interaction avec les psychotropes: à propos de deux cas, Arch Ped, vol.22, pp.536-545, 2015.

J. K. Hicks, J. J. Swen, C. F. Thorn, K. Sangkuhl, E. D. Kharasch et al., Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants, Clin Pharmacol Ther, vol.93, pp.402-410, 2013.

D. Allorge and M. A. Loriot, La pharmacogénétique ou la promesse d'une médecine personnalisée : variations du métabolisme et du transport des médicaments, Ann Biol Clin (Paris), vol.62, pp.499-511, 2004.

F. R. Sallee, C. L. Devane, and R. E. Ferrell, Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency, J Child Adolesc Psychopharmacol, vol.10, pp.27-34, 2000.

C. Kawanishi, S. Lundgren, H. Agren, and L. Bertilsson, Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study, Eur J Clin Pharmacol, vol.59, pp.803-810, 2004.

I. Youngster, D. A. Zachor, L. V. Gabis, A. Bar-chaim, P. Benveniste-levkovitz et al., CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study, Dev Med Child Neurol, vol.56, pp.990-994, 2014.

A. Butwicka, S. Krystyna, W. Retka, and T. Wola?czyk, Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency, Eur J Pediatr, vol.173, pp.1639-1681, 2014.

C. A. Prows, T. G. Nick, S. N. Saldaña, S. Pathak, C. Liu et al., Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients, J Child Adolesc Psychopharmacol, vol.19, pp.385-94, 2009.

B. Almoguera, R. Riveiro-alvarez, J. Lopez-castroman, P. Dorado, C. Vaquero-lorenzo et al., CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment, Pharmacogenet Genomics, vol.23, pp.627-657, 2013.

L. Nussbaum, R. Grãdinaru, N. Andreescu, V. Dumitrascu, A. Tudor et al., The response to atypical antipsychotic drugs in correlation with the CYP2D6 genotype: clinical implications and perspectives, Farmacia, vol.62, pp.1191-201, 2014.

M. G. Scordo, A. P. Caputi, D. 'arrigo, C. Fava, G. Spina et al., Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population, Pharmacol Rest, vol.50, pp.195-200, 2004.

E. Aklillu, I. Persson, L. Bertilsson, I. Johansson, F. Rodrigues et al., Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles, J Pharmacol Exp Ther, vol.278, pp.441-447, 1996.

L. A. Nussbaum, V. Dumitra?cu, A. Tudor, R. Gr?dinaru, N. Andreescu et al., Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype, Romanian J Morphol Embryol, vol.55, pp.877-84, 2014.

W. H. Chou, F. X. Yan, J. De-leon, J. Barnhill, T. Rogers et al., Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness, J Clin Psychopharmacol, vol.20, pp.246-51, 2000.

K. K. Filipski, L. E. Mechanic, R. Long, and A. N. Freedman, Pharmacogenomics in oncology care. Front Genet, vol.5, p.73, 2014.

U. Ozomaro, C. Wahlestedt, and C. B. Nemeroff, Personalized medicine in psychiatry: problems and promises, BMC Med, vol.11, p.132, 2013.

K. Kaufmann, J. Birmaher, B. Axelson, D. Perepletchikova, F. Brent et al., , 2016.

D. Sur,

H. A. Leponex, , 2017.

, HAS commission de la transparence

S. Bulteau, C. Vigneau, M. Bronnec, F. Etcheverrigaray, B. Maulaz et al., Modalités de surveillance des sels de lithium en psychiatrie: des guidelines à la pratique, Ann Med Psychol Rev Psychiatr, vol.174, pp.64-73, 2016.

H. Häfner and B. Nowotny, Epidemiology of early-onset schizophrenia, Eur Arch Psychiatry Clin Neurosci, vol.245, pp.80-92, 1995.

G. Koren, J. Cairns, D. Chitayat, A. Gaedigk, and S. J. Leeder, Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother, The Lancet, vol.368, p.704, 2006.

C. Fabbri and A. Serretti, Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies, Neurosci Lett [Internet]. juin, 2018.

D. Sur,

E. J. Brandl, J. L. Kennedy, and D. J. Müller, Pharmacogenetics of Antipsychotics. Can J Psychiatry Rev Can Psychiatr, vol.59, pp.76-88, 2014.

M. Ingelman-sundberg, A. Persson, and M. M. Jukic, Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates, Pharmacogenomics, vol.15, pp.1841-1845, 2014.

, de mes chers condisciples et devant l effigie d Hippocrate

, Je promets et je jure d être fide`le aux lois de l honneur et de la probite´ dans l exercice de la Me´decine

, Je respecterai toutes les personnes, leur autonomie et leur volonte´, sans discrimination

, J interviendrai pour les prote´ger si elles sont vulne´rables ou menace´es dans leur inte´grite´ ou leur dignite´

, Me?me sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l humanite´

, J informerai les patients des de´cisions envisage´es, de leurs raisons et de leurs

, Admis dans l intimite´ des personnes, je tairai les secrets qui me seront confie´s et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement la vie ni ne provoquerai de´libe´re´ment la mort

, Je pre´serverai l inde´pendance ne´cessaire et je n entreprendrai rien qui de´passe mes compe´tences

, Je perfectionnerai mes connaissances pour assurer au mieux ma mission

, Que les hommes m accordent leur estime si je suis fide`le à mes promesses. Que je sois couvert d opprobre et me´prise´ si j y manque